31 related articles for article (PubMed ID: 3043637)
1. Autoantibodies against type I IFNs in patients with Ph-negative myeloproliferative neoplasms.
Borsani O; Bastard P; Rosain J; Gervais A; Sant'Antonio E; Vanni D; Casetti IC; Pietra D; Trotti C; Catricalà S; Ferretti VV; Malcovati L; Arcaini L; Casanova JL; Borghesi A; Rumi E
Blood; 2022 Apr; 139(17):2716-2720. PubMed ID: 35100354
[No Abstract] [Full Text] [Related]
2. [Treatment of hematologic diseases with alpha interferon].
Castaigne S
Bull Cancer; 1988; 75(9):859-62. PubMed ID: 3207895
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic considerations for use of immunomodulators in the treatment of ataxia-telangiectasia.
Stebbing N
Kroc Found Ser; 1985; 19():339-52. PubMed ID: 3934346
[TBL] [Abstract][Full Text] [Related]
4. Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases.
Cameron RB; McIntosh JK; Rosenberg SA
Cancer Res; 1988 Oct; 48(20):5810-7. PubMed ID: 3262413
[TBL] [Abstract][Full Text] [Related]
5. [Interferon as a sensitizing agent toward chemotherapy in a case of multiple myeloma refractory to treatment].
Seminara P; Codacci-Pisanelli G; Aronne T; Ercoli L; Avella A; Bonomo L
Recenti Prog Med; 1988 Oct; 79(10):415-6. PubMed ID: 3247510
[No Abstract] [Full Text] [Related]
6. [Interferon alpha in the treatment of malignant hematologic diseases].
Steruská M
Vnitr Lek; 1989 Dec; 35(12):1164-70. PubMed ID: 2633454
[TBL] [Abstract][Full Text] [Related]
7. [New biomodulator treatment, treatment with interferon alpha in hematology and treatment using interleukin 2].
Castaigne S; Degos L
Rev Prat; 1988 Jun; 38(17):1069-72. PubMed ID: 3043637
[No Abstract] [Full Text] [Related]
8. [Kinetic and immunological considerations on the therapy of immunoproliferative disorders].
Pileri A; Boccadoro M; Conte P
Recenti Prog Med; 1979 Feb; 66(2):103-15. PubMed ID: 375339
[No Abstract] [Full Text] [Related]
9. [Interferons in the treatment of hematological diseases].
Jantunen E; Nousiainen T
Duodecim; 1998; 114(12):1240-7. PubMed ID: 11524770
[No Abstract] [Full Text] [Related]
10. [Interferon-alfa in the treatment of myeloproliferative diseases].
Adam Z
Vnitr Lek; 1993 Dec; 39(12):1210-8. PubMed ID: 8310673
[TBL] [Abstract][Full Text] [Related]
11. Clinical uses for interferon in the treatment of cancer. A critical review.
Ringenberg QS; Patterson WP
Mo Med; 1988 Jan; 85(1):21-6. PubMed ID: 3277031
[No Abstract] [Full Text] [Related]
12. Immunotherapy: the old and the new.
Oldham RK; Smalley RV
J Biol Response Mod; 1983; 2(1):1-37. PubMed ID: 6196449
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
